{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicdmv2taw3wget5dxgeq3xu2ccfbwkz3a7hs5v27ab5qmtimzvy7m",
    "uri": "at://did:plc:tpd4fxsnyhzzhnj6g4llqsfn/app.bsky.feed.post/3ml274wyxha52"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiasbo3lem2akmhb2w5zpvxgslx7wznh3gxomrh4uimrauuru7pkiy"
    },
    "mimeType": "image/jpeg",
    "size": 36081
  },
  "path": "/news/11828976/health-canada-second-drug-alzheimers/",
  "publishedAt": "2026-05-04T16:21:39.000Z",
  "site": "https://globalnews.ca",
  "tags": [
    "Canada",
    "Health",
    "Alzheimer's",
    "donanemab",
    "Eli Lilly",
    "Health Canada"
  ],
  "textContent": "This is the second disease-slowing drug for Alzheimer’s that has been approved in Canada, after Health Canada approved lecanemab, commercially known as Leqembi, in October 2025.",
  "title": "‘Hopeful milestone’: Health Canada approves 2nd drug to slow Alzheimer’s"
}